Press release
Investigation announced for Long-Term Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) over potential Wrongdoing

An investigation on behalf of current long term investors in Actinium Pharmaceuticals, Inc. (NYSE: ATNM) shares.
Investors who are current long term investors in Actinium Pharmaceuticals, Inc. (NYSE: ATNM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: ATNM stocks follows a lawsuit filed against Actinium Pharmaceuticals, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NYSE: ATNM stocks, concerns whether certain Actinium Pharmaceuticals, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that, the Defendants failed to disclose that the Company's data from the Sierra Trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA, that the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate Sierra's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA, that as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved, and that as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) over potential Wrongdoing here
News-ID: 4073049 • Views: …
More Releases from Shareholders Foundation, Inc.

Investors who lost money with shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RC …
An investor, who purchased shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), filed a lawsuit over alleged violations of Federal Securities Laws by Rocket Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have certain options and for certain investors are short and strict deadlines running. Deadline: August 11, 2025. NASDAQ: RCKT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…

Lawsuit filed for Investors who lost money with shares of Vestis Corporation (NY …
An investor, who purchased shares of Vestis Corporation (NYSE: VSTS), filed a lawsuit over alleged violations of Federal Securities Laws by Vestis Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Vestis Corporation (NYSE: VSTS) have certain options and for certain investors are short and strict deadlines running. Deadline: August 8, 2025. NYSE: VSTS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…

Napco Security Technologies, Inc. (NASDAQ: NSSC) Investor Alert: Deadline in Law …
A deadline is coming up on June 24, 2025 in the lawsuit filed for certain investors of Napco Security Technologies, Inc. (NASDAQ: NSSC) over alleged securities laws violations by Napco Security Technologies, Inc.
Investors who purchased shares of Napco Security Technologies, Inc. (NASDAQ: NSSC) have certain options and there are strict and short deadlines running. Deadline: June 24, 2025. Napco Security Technologies, Inc. (NASDAQ: NSSC) stockholders should contact the Shareholders…

Investors who lost money with shares of PepGen Inc. (NASDAQ: PEPG) should contac …
An investor, who purchased shares of PepGen Inc. (NASDAQ: PEPG), filed a lawsuit over alleged violations of Federal Securities Laws by PepGen Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of PepGen Inc. (NASDAQ: PEPG) have certain options and for certain investors are short and strict deadlines running. Deadline: August 8, 2025. NASDAQ: PEPG investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
More Releases for Actinium
Radioimmunotherapy Market Dynamics (DROC & PEST Analysis) with Top Company Profi …
The Radioimmunotherapy market research report helps decision-makers to improve their business plans and ensure long-term success. The extensive research study provides in-depth information on Global Innovations, New Business Techniques, New product development, M&A, Recent Trends, Covid19 Impact analysis & Revenue Opportunities, DROC, PEST Analysis, Capital Investment, Technology Innovation, and Future Trends Outlook.
The Radioimmunotherapy Market size was valued at US$ 81.9 Mn in 2018 and is expected to grow at a compound annual growth rate…
Radioimmunotherapy Market 2020 | Leading Competitors - Actinium Pharmaceuticals, …
This detailed market study covers radioimmunotherapy market growth potentials which can assist the stake holders to understand key trends and prospects in radioimmunotherapy market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the market's growth potential, which can help investors identify scope and opportunities. The analysis also…
Alpha Emitters Market 2019 Future Trends by IBA GROUP, LANTHEUS MEDICAL IMAGING, …
The global alpha emitters market was valued at approximately USD 5000 million in 2017 and is expected to register a CAGR of approximately 9% during the forecast period. North America holds the largest geographical market, with a share of approximately 47% of the global market.
Detailed Sample Copy of Alpha Emitters Market with Updated Analysis @ https://marketprognosis.com/sample-request/16677
Increasing Incidence of Cardiac and Cancer Ailments
The American Cancer Society, the leading body in cancer…
Myelodysplastic Syndrome Market by Top Company Profiles - Celgene, Novartis, Ots …
Global Myelodysplastic Syndrome Market report detailed by major player (Celgene, Novartis, Otsuka, Actinium Pharmaceuticals, Acceleron Pharma, Bellicum Pharmaceuticals and more…), Types, Applications. The report shows the industry chain structure, Research Methodology Data Source (Primary, Secondary) and market forecast 2024.
The report offers a chance to unlock wide insights with regard to the world Myelodysplastic Syndrome Market and assists to create intelligent strategic selections. The analysis discloses a number of the many…
Alpha Emitters Market 2019 Segmented by Manufacturers (IBA GROUP, LANTHEUS MEDIC …
The global alpha emitters market was valued at approximately USD 5000 million in 2017 and is expected to register a CAGR of approximately 9% during the forecast period. North America holds the largest geographical market, with a share of approximately 47% of the global market.
Detailed Sample Copy of Alpha Emitters Market with Updated Analysis @ https://marketprognosis.com/sample-request/16677
Increasing Incidence of Cardiac and Cancer Ailments
The American Cancer Society, the leading body in cancer…
Global Myelodysplastic Syndrome Market Forecast 2018-2025 Novartis, Otsuka, Acti …
2018 Global Myelodysplastic Syndrome Market Report is a professional and in-depth analysis report on the world's major regional market conditions of the Myelodysplastic Syndrome market, specializing in the most regions (North America, Europe and Asia etc.) and main countries (United States, Germany, United Kingdom, Japan, India, Republic of Korea and China etc.).
Inquiry for Sample of Report @ https://bit.ly/2MWvrI5
The report first of all introduced the Myelodysplastic Syndrome basics: definitions, classifications, applications…